Targeting LLT1 as a potential immunotherapy option for cancer patients non-responsive to existing checkpoint therapies in multiple solid tumors
The biomarker analysis revealed a clear association between elevated LLT1 expression and an immunosuppressive TME in patient cohorts from TCGA and clinical databases. Therefore, this study provides a foundation for utilizing LLT1 as a potential target to improve clinical responses in ICI non-responsive patients with upregulated LLT1.
Authors
- Maloy Ghosh (ORCID: https://orcid.org/0000-0001-5161-8917)
- Soorya Gnanasegaran
- Yogendra Manjunath
- Subith Krishna
- M. S. Madhusudhan (ORCID: https://orcid.org/0000-0002-2889-5884)
- Sanghamitra Bhattacharjee
- Shalini Kashipathi
- Ashvini Kumar Dubey
- Tirtha Mandal
- Anurag Tiwari (ORCID: https://orcid.org/0000-0001-8490-7483)
- Golding Rodrigues
Institutions
- Indian Institute of Science Education and Research Pune (IN)
- Stempeutics (India) (IN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1186/s12885-024-13074-z
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57